| 宋泓杉,张 健,赵付雅,郝 丽,李爱东.乳腺癌转移风险评估标志物的研究进展[J].,2017,17(28):5594-5596 |
| 乳腺癌转移风险评估标志物的研究进展 |
| Research Advance in Biomarkers for Risk Assessment of Metastatic Breast Cancer |
| 投稿时间：2016-10-28 修订日期：2016-11-23 |
| DOI：10.13241/j.cnki.pmb.2017.28.045 |
| 中文关键词: 乳腺癌 转移风险 人表皮生长因子受体-2 尿激酶型纤溶酶原激活剂/纤溶酶原激活物抑制剂1 基因表达谱 |
| 英文关键词: Breast cancer Metastasis risk Her-2 uPA/PAI1 Gene expression profile |
| 基金项目: |
|
| 摘要点击次数: 161 |
| 全文下载次数: 110 |
| 中文摘要: |
| 摘要：肿瘤转移是造成乳腺癌患者死亡的主要原因，为提高生存期，有大约80 %的患者选择了辅助治疗，然而只有其中一部分患者最后真正发生了转移。那些实际转移风险很低，却仍然选择了进一步放疗、化疗、内分泌或免疫治疗的患者，不仅受到了治疗副作用的伤害、也造成了医疗资源的浪费。因此，准确评价患者的转移风险对指导临床工作格外重要。以肿瘤的基因改变和转移过程为切入点，利用先进的分子技术，已有数项指标通过严谨的实验论证，认为可以评估乳腺癌的转移风险，本文将对其进行简要的介绍和分析。 |
| 英文摘要: |
| ABSTRACT: Metastasis is the main cause of death in breast cancer patients, more than 80 % patients have chosen adjuvant therapy but only part of them really developed tumor metastasis at last. Patients who chose further radiotherapy, chemotherapy, endocrine and immune therapy with low risk of metastasis, not only harmed themselves by side effects, but also caused the waste of medical resource. Therefore accurate metastatic prognostic markers are important for clinical work. Take the genetic changes and metastasis of tumor as a starting point, by the use of advanced molecular techniques, there have been several indicators through rigorous experiments demonstrate that you can assess the risk of breast cancer metastasis, this article will be a brief introduction and analysis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
